Evinacumab(anti-ANGPTL3)

Evinacumab is a monoclonal antibody that targets, binds to, and pharmacologically inhibits ANGPTL3, which can act as a complementary agent to other LDL-C lowering regimens for patients aged 12 or older with HoFH.

Evinacumab(anti-ANGPTL3)

Selleck's Evinacumab(anti-ANGPTL3) has been cited by 0 publication

1 Customer Review

Purity & Quality Control

Batch: Purity: 98% Protein concentration: 6.5mg/ml Endotoxin Level: <1EU/mg
98

Biological Activity

Description Evinacumab is a monoclonal antibody that targets, binds to, and pharmacologically inhibits ANGPTL3, which can act as a complementary agent to other LDL-C lowering regimens for patients aged 12 or older with HoFH.

Product Details

CAS No. 1446419-85-7
Molecular Weight 150 kDa
Isotype human IGg1, λ
Application Evinacumab(anti-ANGPTL3)
Source CHO
Purification Protein G
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Evinacumab(anti-ANGPTL3) | Evinacumab(anti-ANGPTL3) supplier | purchase Evinacumab(anti-ANGPTL3) | Evinacumab(anti-ANGPTL3) cost | Evinacumab(anti-ANGPTL3) manufacturer | order Evinacumab(anti-ANGPTL3) | Evinacumab(anti-ANGPTL3) distributor